HK1211038A1 - Anti-kit antibodies and uses thereof kit - Google Patents

Anti-kit antibodies and uses thereof kit

Info

Publication number
HK1211038A1
HK1211038A1 HK15111765.3A HK15111765A HK1211038A1 HK 1211038 A1 HK1211038 A1 HK 1211038A1 HK 15111765 A HK15111765 A HK 15111765A HK 1211038 A1 HK1211038 A1 HK 1211038A1
Authority
HK
Hong Kong
Prior art keywords
kit
antibodies
kit antibodies
Prior art date
Application number
HK15111765.3A
Other languages
English (en)
Chinese (zh)
Inventor
亞龍．哈達利
伊麗莎白．
．曼德爾-鮑什
弗朗西斯．約瑟夫．凱爾
蒂莫西．大衛．瓊斯
芳拉．克萊爾．亞歷山德拉．佩里
Original Assignee
Kolltan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48916252&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1211038(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kolltan Pharmaceuticals Inc filed Critical Kolltan Pharmaceuticals Inc
Publication of HK1211038A1 publication Critical patent/HK1211038A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
HK15111765.3A 2012-07-25 2015-11-30 Anti-kit antibodies and uses thereof kit HK1211038A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261675751P 2012-07-25 2012-07-25
US201261675762P 2012-07-25 2012-07-25
PCT/US2013/051815 WO2014018625A1 (en) 2012-07-25 2013-07-24 Anti-kit antibodies and uses thereof

Publications (1)

Publication Number Publication Date
HK1211038A1 true HK1211038A1 (en) 2016-05-13

Family

ID=48916252

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111765.3A HK1211038A1 (en) 2012-07-25 2015-11-30 Anti-kit antibodies and uses thereof kit

Country Status (20)

Country Link
US (6) US9334332B2 (pt)
EP (3) EP3381943B1 (pt)
JP (4) JP6307075B2 (pt)
KR (1) KR102268351B1 (pt)
CN (3) CN110256559B (pt)
AU (1) AU2013295848B2 (pt)
BR (1) BR112015001459B1 (pt)
CA (1) CA2880007C (pt)
DK (2) DK2877493T3 (pt)
ES (1) ES2673847T3 (pt)
HK (1) HK1211038A1 (pt)
IL (1) IL236874B (pt)
MX (1) MX360620B (pt)
NZ (2) NZ731881A (pt)
PH (1) PH12015500113A1 (pt)
RU (1) RU2681730C2 (pt)
SG (1) SG11201500489YA (pt)
TW (1) TWI596113B (pt)
WO (1) WO2014018625A1 (pt)
ZA (1) ZA201500457B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
JP6307075B2 (ja) 2012-07-25 2018-04-18 セルデックス セラピューティクス，インコーポレーテッド 抗ｋｉｔ抗体及びその使用
CA2903772A1 (en) 2013-03-15 2014-09-25 Novartis Ag Antibody drug conjugates
WO2015050959A1 (en) * 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
WO2015179737A2 (en) * 2014-05-23 2015-11-26 Kolltan Pharmaceuticals, Inc. Treatment of eosinophil or mast cell related disorders
US10889646B2 (en) 2015-03-25 2021-01-12 Children's Hospital Medical Center Use of KIT inhibitors to condition subjects for a hematopoietic stem cell (HSC) transplantation
WO2017219029A2 (en) 2016-06-17 2017-12-21 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+cells
MA45602A (fr) * 2016-07-08 2019-05-15 Staten Biotechnology B V Anticorps anti-apoc3 et leurs méthodes d'utilisation
JOP20190155A1 (ar) 2016-12-21 2019-06-23 Novartis Ag مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
TWI825007B (zh) 2017-01-20 2023-12-11 德商海德堡醫藥研究有限責任公司 用於cd137＋細胞耗盡（depletion）之組合物及方法
CA3063368A1 (en) 2017-05-12 2018-11-15 The Jackson Laboratory Nsg mice lacking mhc class i and class ii
US20180371089A1 (en) * 2017-06-22 2018-12-27 Development Center For Biotechnology Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecific antibody and uses thereof in caner therapy
US11712026B2 (en) 2017-10-18 2023-08-01 The Jackson Laboratory Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development
GB201802201D0 (en) 2018-02-09 2018-03-28 Ultrahuman Five Ltd Binding agents
KR102716514B1 (ko) * 2018-10-10 2024-10-15 주식회사 노벨티노빌리티 신규 항-c-KIT 항체
WO2020102095A1 (en) * 2018-11-12 2020-05-22 Blueprint Medicines Corporation Avapritinib resistance of kit mutants
US11208482B2 (en) * 2018-11-26 2021-12-28 Forty Seven, Inc. Humanized antibodies against c-Kit
USD966445S1 (en) * 2019-02-13 2022-10-11 Global Sports Innovation LTD Sports training device
EP3958899A4 (en) * 2019-04-24 2023-08-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND USES THEREOF
JP2022530438A (ja) * 2019-04-24 2022-06-29 マジェンタ セラピューティクス インコーポレイテッド 抗ｃｄ１１７抗体薬物複合体およびその使用
EP4021579A1 (en) * 2019-08-30 2022-07-06 Qilu Puget Sound Biotherapeutics Corporation Anti-cd20 antibodies, anti-cd37 antibodies, and mixtures thereof
KR20210063782A (ko) * 2019-11-25 2021-06-02 주식회사 노벨티노빌리티 c-kit에 대한 항체 및 이의 용도
US11297054B1 (en) * 2020-10-06 2022-04-05 International Business Machines Corporation Authentication system(s) with multiple authentication modes using one-time passwords of increased security
MX2023008518A (es) * 2021-01-22 2023-07-28 Celldex Therapeutics Inc Anticuerpos anti-kit y usos de los mismos.
CN118355025A (zh) * 2021-10-07 2024-07-16 新奇贵族公司 肥大细胞相关障碍的治疗

Family Cites Families (323)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5108912A (en) 1987-01-30 1992-04-28 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5037651A (en) 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5268358A (en) 1988-12-08 1993-12-07 Cor Therapeutics, Inc. PDGF receptor blocking peptides
US5734033A (en) 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US7144731B2 (en) 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US20050276784A1 (en) 1990-08-27 2005-12-15 Solan-Kettering Institute For Cancer Research Ligand for the c-kit receptor and methods of use thereof
US20030125519A1 (en) 1990-08-27 2003-07-03 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
CA2074825C (en) 1990-12-14 2005-04-12 Daniel J. Capon Chimeric chains for receptor-associated signal transduction pathways
AU1411092A (en) 1991-01-31 1992-09-07 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
ATE169031T1 (de) * 1991-04-05 1998-08-15 Univ Washington Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5545533A (en) 1991-05-25 1996-08-13 Boehringer Mannheim Gmbh Monoclonal antibodies against c-kit and method of detecting a malignancy using c-kit specific antibodies
DE4205148A1 (de) 1991-05-25 1993-01-21 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen c-kit
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
USRE38506E1 (en) 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
CA2124958C (en) 1991-12-02 2007-02-13 Vanitha Ramakrishnan Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
EP0548867A2 (en) 1991-12-23 1993-06-30 Yeda Research And Development Co. Ltd. Soluble stem cell factor (SFC)-receptor
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6271242B1 (en) 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US6001803A (en) 1992-04-23 1999-12-14 Sloan-Kettering Institute For Cancer Research Composition of c-kit ligand, GM-CSF, and TNF-α and method of use
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP1087013B1 (en) 1992-08-21 2009-01-07 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
DE69434969T2 (de) 1993-07-15 2008-01-10 Cancer Research Campaign Technology Ltd. Verbindungen die zur herstellung von protein-tyrosin-kinase-inhibitor-prodrogen verwendet werden können
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5925376C1 (en) 1994-01-10 2001-03-20 Madalene C Y Heng Method for treating psoriasis using selected phosphorylase kinase inhibitor and additional compounds
US5618709A (en) 1994-01-14 1997-04-08 University Of Pennsylvania Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
CZ25697A3 (en) 1994-07-29 1997-09-17 Smithkline Beecham Plc Novel compounds
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5911995A (en) 1994-08-19 1999-06-15 Regents Of The University Of Minnesota EGF-genistein conjugates for the treatment of cancer
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
JP4026848B2 (ja) 1995-01-17 2007-12-26 ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 免疫原の受容体特異的経上皮輸送
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5998596A (en) 1995-04-04 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of protein kinase activity by aptameric action of oligonucleotides
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5911988A (en) 1995-04-28 1999-06-15 Bayer Corporation Method for treating asthma using SCF antibody
US6034235A (en) 1995-06-01 2000-03-07 Tadamitsu Kishimoto Growth inhibitor for leukemia cell comprising antisense oligonucleotide derivative to wilms tumor gene (WT1)
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6936259B2 (en) 1995-06-08 2005-08-30 University Of Saskatchewan CAMP factor of Streptococcus uberis
GB9515975D0 (en) 1995-08-04 1995-10-04 Zeneca Ltd Chemical compounds
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US6127366A (en) 1995-11-22 2000-10-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CZ293296B6 (cs) 1995-12-08 2004-03-17 Janssen Pharmaceutica N.V. (Imidazol-5-yl)methyl-2-chinolinonové deriváty inhibující farnesyl protein transferázu
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
DE19600589C1 (de) * 1996-01-10 1997-01-16 Univ Eberhard Karls Antikörper A3C6E2
US5958769A (en) 1996-01-18 1999-09-28 Fred Hutchinson Cancer Research Center Compositions and methods for mediating cell cycle progression
US6090948A (en) 1996-01-30 2000-07-18 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000504014A (ja) 1996-01-30 2000-04-04 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
KR20030096450A (ko) 1996-03-22 2003-12-31 휴먼 게놈 사이언시즈, 인코포레이티드 고사 유도 분자 ⅱ
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US6080870A (en) 1996-04-03 2000-06-27 Merck & Co., Inc. Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5883105A (en) 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5891889A (en) 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US6300501B1 (en) 1996-05-22 2001-10-09 Warner-Lambert Company Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5910417A (en) 1996-05-31 1999-06-08 National Jewish Center For Immunology And Respiratory Medicine Regulation of cytokine production in a hematopoietic cell
US5648239A (en) 1996-06-21 1997-07-15 Incyte Pharmaceuticals, Inc. Human camp-dependent protein kinase inhibitor homolog
BR9709974A (pt) 1996-06-27 1999-08-10 Pfizer Derivados de 2-(2-oxo-etidileno)-imidazolidin-4-ona e seu uso como inibidores da transferase da proteina de farnesila
WO1998006433A1 (fr) 1996-08-12 1998-02-19 Yoshitomi Pharmaceutical Industries, Ltd. MEDICAMENTS COMPRENANT UN INHIBITEUR DE LA Rho KINASE
US6030982A (en) 1996-09-13 2000-02-29 Schering Corporationm Compounds useful for inhibition of farnesyl protein transferase
US6040305A (en) 1996-09-13 2000-03-21 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5945429A (en) 1996-09-13 1999-08-31 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5885834A (en) 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
IL129242A0 (en) 1996-10-01 2000-02-17 Cima Labs Inc Taste-masked microcapsule compositions and methods of manufacture
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US6013662A (en) 1996-12-30 2000-01-11 Rhone-Poulenc Rorer S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
US5939439A (en) 1996-12-30 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6093737A (en) 1996-12-30 2000-07-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6414145B1 (en) 1997-01-29 2002-07-02 Zeneca Limited Imidazolyl compounds as inhibitors of farnesyl-protein tranferase
ZA981080B (en) 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
AU6763098A (en) 1997-03-19 1998-10-12 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6211193B1 (en) 1997-06-17 2001-04-03 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6051582A (en) 1997-06-17 2000-04-18 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6228865B1 (en) 1997-06-17 2001-05-08 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6239140B1 (en) 1997-06-17 2001-05-29 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6159984A (en) 1997-06-17 2000-12-12 Schering Corporation Farnesyl protein transferase inhibitors
US6225322B1 (en) 1997-06-17 2001-05-01 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
DE19727814C1 (de) 1997-06-30 1998-10-01 Univ Eberhard Karls Anitkörper 4G8B4B12
PT1011648E (pt) 1997-08-15 2002-03-28 Cephalon Inc Combinacao do inibidor de tirosina cinase e castracao quimica para tratar o cancro da prostata
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6555367B1 (en) 1997-10-10 2003-04-29 The United States Of America As Represented By The Department Of Health And Human Services Complex of biotinylated viral vector and ligand for targeted gene delivery
US6103723A (en) 1997-10-17 2000-08-15 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP1025089A1 (en) 1997-10-22 2000-08-09 Zeneca Limited Imidazole derivatives and their use as farnesyl protein transferase inhibitors
US6342765B1 (en) 1997-10-22 2002-01-29 Astrazeneca Uk Limited Imidazole derivatives and their use as farnesyl protein transferase inhibitors
JP4441112B2 (ja) 1997-11-03 2010-03-31 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 新脈管形成および腫瘍増殖のインヒビターであるｖｅｇｉ
US6124465A (en) 1997-11-25 2000-09-26 Rhone-Poulenc S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
JP3548118B2 (ja) 1997-11-28 2004-07-28 エルジ ケミカル リミテッド ファルネシル転移酵素抑制活性を有するイミダゾール誘導体およびその製造方法
US6054466A (en) 1997-12-04 2000-04-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US6335156B1 (en) 1997-12-18 2002-01-01 The Johns Hopkins University School Of Medicine 14-3-3σ arrests the cell cycle
PT1058683E (pt) 1998-02-02 2003-04-30 Lg Chemical Ltd Inibidores da farnesil-transferase com uma estrutura de piperidina e seu processo de preparacao
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
EP1071700B1 (en) 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
DK1076663T3 (da) 1998-04-27 2004-06-01 Warner Lambert Co Funktionaliserede alkyl- og alkenylsidekædederivater af glycinamider som farnesyltransferaseinhibitorer
JP2002512776A (ja) 1998-04-28 2002-05-08 スミスクライン・ビーチャム・コーポレイション 免疫原性の低下したモノクローナル抗体
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
BR9911869A (pt) 1998-07-06 2001-03-27 Janssen Pharmaceutica Nv Inibidores da transferase da proteìna farnesil para o tratamento das artropatias
US6034053A (en) 1998-07-13 2000-03-07 Wayne Hughes Institute EGF-isoflavone conjugates for the prevention of restenosis
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
US6372747B1 (en) 1998-12-18 2002-04-16 Schering Corporation Farnesyl protein transferase inhibitors
US6362188B1 (en) 1998-12-18 2002-03-26 Schering Corporation Farnesyl protein transferase inhibitors
FR2787327B1 (fr) 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
US6432959B1 (en) 1998-12-23 2002-08-13 Schering Corporation Inhibitors of farnesyl-protein transferase
AU779008C (en) 1999-01-11 2005-06-30 Princeton University High affinity inhibitors for target validation and uses thereof
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
DK2270150T4 (da) 1999-04-09 2019-08-26 Kyowa Hakko Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle.
WO2000061637A1 (en) 1999-04-14 2000-10-19 Smithkline Beecham Corporation Erythropoietin receptor antibodies
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6143766A (en) 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
US6576812B1 (en) 1999-05-06 2003-06-10 The Trustees Of Columbia University In The City Of New York Compound screening assays using a transgenic mouse model of human skin diseases
US6989248B2 (en) 1999-05-06 2006-01-24 The Trustees Of Columbia University In The City Of New York Methods of use of compounds which inhibit the stem cell signaling pathway
US6458935B1 (en) 1999-06-23 2002-10-01 Merck & Co., Inc. Radiolabeled farnesyl-protein transferase inhibitors
CA2388245C (en) 1999-10-19 2012-01-10 Tatsuya Ogawa The use of serum-free adapted rat cells for producing heterologous polypeptides
EP1094110A1 (en) 1999-10-21 2001-04-25 Leadd B.V. Apoptosis inducing proteinaceous substance
JP2003513939A (ja) 1999-11-12 2003-04-15 アドバンスト リサーチ アンド テクノロジー インスティテュート，インコーポレイティド 神経繊維腫症タイプ１（ｎｆ１）の阻害方法
WO2001044301A1 (en) 1999-11-29 2001-06-21 Unilever Plc Immobilized single domain antigen-binding molecules
MXPA02006263A (es) 1999-12-22 2004-02-26 Sugen Inc Metodos de modulacion de la funcion de la cinasa de tirosina c-kit de la proteina con compuestos de indolinona.
US6403581B1 (en) 2000-01-19 2002-06-11 American Cyanamid Company Method of inhibition of farnesyl-protein transferase using substituted benz (cd) indol-2-imine and-amine derivatives
AU4314801A (en) 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US20110091428A1 (en) 2000-07-31 2011-04-21 New York Medical College Compositions of adult organ stem cells and uses thereof
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
EP2314686B2 (en) 2000-10-06 2023-06-21 Kyowa Kirin Co., Ltd. Cells producing antibody compositions
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US6914947B2 (en) 2001-02-28 2005-07-05 Telefonaktiebolaget L M Ericsson (Publ) Method and apparatus for handling time-drift
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
WO2002084290A1 (fr) 2001-04-13 2002-10-24 Chugai Seiyaku Kabushiki Kaisha Procede permettant de quantifier l'expression d'antigenes
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
EP2277991A1 (en) 2001-08-21 2011-01-26 Ventana Medical Systems, Inc. Method and quantification assay for determining c-kit/SCF/pAKT status
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
JP2005516958A (ja) * 2001-12-20 2005-06-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド Ｔｒａｉｌレセプターに免疫特異的に結合する抗体
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
WO2003102017A2 (en) 2002-06-03 2003-12-11 Centocor, Inc. Anti-relp fusion antibodies, compositions, methods and uses
AU2003245752A1 (en) 2002-06-28 2004-01-19 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
EP3502133A1 (en) 2002-09-27 2019-06-26 Xencor, Inc. Optimized fc variants and methods for their generation
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP2006507322A (ja) 2002-11-14 2006-03-02 シンタルガ・ビーブイ 多重自己脱離放出スペーサーとして構築されたプロドラッグ
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US9243064B2 (en) 2003-01-31 2016-01-26 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
EP2100619B1 (en) 2003-02-20 2014-02-12 Seattle Genetics, Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of immune disorders
US20050281828A1 (en) 2003-03-04 2005-12-22 Bowdish Katherine S Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CA2537055A1 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
US7303893B1 (en) 2003-08-28 2007-12-04 Takeda San Diego, Inc. Crystallization of c-KIT tyrosine kinase leading to autoinhibited crystal structure
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US20050226867A1 (en) 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
CA2543318C (en) 2003-10-22 2013-01-08 B. Rao Vishnuvajjala Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
JP2007517502A (ja) 2003-12-04 2007-07-05 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 活性なｋｉｔチロシンキナーゼ受容体のモジュレーターを同定する方法
NL1027975C2 (nl) 2004-01-09 2005-12-23 Pfizer Antilichamen tegen MAdCAM.
PT1720881E (pt) 2004-03-01 2013-02-04 Spirogen Sarl Derivados de 11-hidroxi-5h-pirrolo[2,1-c][1,4]benzodiazepin- 5-ona como intermediários chave para a preparação de pirrolobenzodiazepinas substituídas em c2
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
US7803535B2 (en) 2004-03-27 2010-09-28 Hanns-Georg Klein Polymorphisms in the NOD2/CARD15 gene
ES2375481T3 (es) 2004-03-30 2012-03-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticuerpos biespecíficos para elegir como diana células que participan en reacciones de tipo alérgico, composiciones y usos de los mismos.
CN1997382A (zh) 2004-05-05 2007-07-11 梅里麦克制药股份有限公司 调节生物活性的双特异性结合剂
GB0410725D0 (en) 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents
EP1753463A2 (en) 2004-06-01 2007-02-21 Genentech, Inc. Antibody drug conjugates and methods
US7329495B2 (en) 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
WO2006017173A1 (en) 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
CA2575901C (en) 2004-08-02 2015-01-27 Amrad Operations Pty. Ltd. A method of treating cancer comprising a vegf-b antagonist
WO2006017538A2 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
EP1786469A2 (en) 2004-09-10 2007-05-23 Wyeth a Corporation of the State of Delaware Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates
CA2586909A1 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
EP1853309A4 (en) 2005-02-23 2008-10-22 Merrimack Pharmaceuticals Inc BISPECIFIC BINDER FOR MODULATING BIOLOGICAL ACTIVITY
US20060222634A1 (en) 2005-03-31 2006-10-05 Clarke Diana L Amnion-derived cell compositions, methods of making and uses thereof
WO2006111759A1 (en) 2005-04-21 2006-10-26 Spirogen Limited Pyrrolobenzodiazepines
CA2606081C (en) 2005-04-26 2013-09-17 Markus M. Heiss Combination of the application of antibodies for immunostimulation together with glucocorticoids
EP2366786A3 (en) 2005-05-05 2012-08-29 VALORISATION HSJ, Société en Commandite Cytokine receptor modulators and uses thereof
WO2007014943A2 (en) 2005-08-01 2007-02-08 Ares Trading S.A. Therapy for neurological diseases
EP1909846B1 (en) 2005-08-05 2018-12-26 Syntarga B.V. Triazole-containing releasable linkers, conjugates comprising the same and processes for their preparation
NZ566982A (en) 2005-09-26 2011-06-30 Medarex Inc Duocarmycin drug conjugates
DE602006006199D1 (de) 2005-10-05 2009-05-20 Spirogen Ltd 4-ä4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo ä2, 1-cüä1,4übenzodiazepin-8-yloxy)-butyrylaminoü-1h-pyrrol-2-carbonsäurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung
WO2008048671A1 (en) 2006-10-18 2008-04-24 University Of Illinois Embryonic-like stem cells derived from adult human peripheral blood and methods of use
EP3061834B1 (en) 2005-10-21 2020-01-08 The Regents of the University of California Shp-2 gene mutations in melanoma
PL1945665T3 (pl) 2005-10-21 2012-02-29 Genzyme Corp Leki oparte na przeciwciałach z ulepszoną aktywnością adcc
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2007084949A2 (en) 2006-01-18 2007-07-26 The Uab Research Foundation Modulators of cardiac cell hypertrophy and hyperplasia
BRPI0707426A2 (pt) 2006-02-02 2011-05-03 Syntarga Bv composto, conjugado, uso de um composto, composição farmacêutica, processo para preparar uma composição farmacêutica, e, métodos de tratamento de um mamìfero estando em necessidade do mesmo, e de tratamento ou prevenção de um tumor em um mamìfero
EP2606890A1 (en) 2006-04-05 2013-06-26 Novartis AG Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
US20080032989A1 (en) 2006-05-31 2008-02-07 Robinson William H Method of treating inflammatory diseases using tyroskine kinase inhibitors
EP2044118A2 (en) 2006-06-13 2009-04-08 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
JP2009539403A (ja) * 2006-06-13 2009-11-19 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断および処置するための組成物および方法
CN101516191A (zh) 2006-09-28 2009-08-26 默克公司 Saha的胺碱盐和其多晶型物
KR101079520B1 (ko) 2006-10-20 2011-11-03 아이알엠 엘엘씨 Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 수용체를 조절하기 위한 조성물 및 방법
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
US7846434B2 (en) 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
EP3255061B1 (en) 2006-11-03 2021-06-16 The Board of Trustees of the Leland Stanford Junior University Selective immunodepletion of endogenous stem cell niche for engraftment
WO2008059052A1 (en) 2006-11-17 2008-05-22 Innate Pharma Improved methods of using phosphoantigen for the treatment of cancer
WO2008115300A1 (en) 2006-12-01 2008-09-25 Apocell, Inc. C-kit phosphorylation in cancer
WO2008112290A2 (en) 2007-03-12 2008-09-18 Vasgene Therapeutics, Inc. Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
WO2008118391A2 (en) 2007-03-27 2008-10-02 Synta Pharmaceuticals Corp. Triazinone and diazinone derivatives useful as hsp90 inhibitors
US20110268776A1 (en) 2007-04-25 2011-11-03 Schapira Jay N Programmed-release, nanostructured biological construct for stimulating cellular engraftment for tissue regeneration
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
WO2008150261A1 (en) 2007-06-04 2008-12-11 Wyeth Detection and quantitation of calicheamicin
BRPI0812400A2 (pt) 2007-06-05 2014-10-29 Univ Yale Unidade, hibridoma, composição farmacêutica, método para identificar uma unidade, anticorpo isolado a uma unidade de ligação de antígeno do mesmo, molécula peptídica, e, uso da unidade.
AU2007357156B2 (en) 2007-08-01 2013-01-10 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
WO2009021137A2 (en) 2007-08-07 2009-02-12 Purdue Research Foundation Kinase inhibitors and uses thereof
US20100196923A1 (en) 2007-08-14 2010-08-05 Anthony Atala Pluripotent adult stem cells
US7538395B2 (en) 2007-09-21 2009-05-26 Semiconductor Components Industries, L.L.C. Method of forming low capacitance ESD device and structure therefor
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US20090136517A1 (en) 2007-11-28 2009-05-28 Garton Andrew J Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit
CN101932608A (zh) 2007-11-30 2010-12-29 葛兰素集团有限公司 抗原结合构建体
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
WO2009079585A2 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
WO2009088805A2 (en) 2008-01-03 2009-07-16 The Scripps Research Institute Antibody targeting through a modular recognition domain
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
US20110059091A1 (en) 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
WO2009135001A2 (en) 2008-04-30 2009-11-05 University Of Pittsburgh- Commonwealth System Of Higher Education Methods and compositions for regulating th2 and th17 responses
EP2297305A4 (en) 2008-05-15 2013-03-13 Univ Miami ISOLATION OF STEM CELL PRECURSORS AND EXPANSION UNDER NON-ADHESION CONDITIONS
CA2726376A1 (en) 2008-06-13 2009-12-17 Novartis Ag Substituted benzimidazoles for neurofibromatosis
SG192444A1 (en) 2008-06-27 2013-08-30 Univ Indiana Res & Tech Corp Materials and methods for suppressing and/or treating neurofibroma and related tumors
EP2314628A4 (en) 2008-06-30 2013-07-10 Kyowa Hakko Kirin Co Ltd ANTI-CD27 ANTIBODY
JP2011530535A (ja) 2008-08-07 2011-12-22 セントローズ， エルエルシー グリコシド化合物およびその医薬組成物
US8084222B2 (en) 2008-09-26 2011-12-27 Eureka Therapeutics, Inc. Methods for generating host cells
EP2331676A4 (en) 2008-09-26 2012-09-19 Univ Duke GROWTH FACTOR OF A HEMATOPOIETIC STEM CELL
US20110262465A1 (en) 2008-10-22 2011-10-27 Genentech, Inc. Prostate stem cells and uses thereof
AU2009320481C1 (en) 2008-11-03 2016-12-08 Syntarga B.V. Novel CC-1065 analogs and their conjugates
NZ592726A (en) 2008-11-19 2012-12-21 Anthrogenesis Corp Amnion derived adherent cells
US20110281813A1 (en) 2008-12-04 2011-11-17 Cleveland Clinic Method of treating c-kit positive relapsed acute myeloid leukemia
US20100204058A1 (en) 2009-01-28 2010-08-12 Howard Yuan-Hao Chang Profiling for Determination of Response to Treatment for Inflammatory Disease
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
JP2012526542A (ja) * 2009-05-12 2012-11-01 ファイザー・インク 遮断抗ｄｋｋ−１抗体およびその使用
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
US20120253017A1 (en) 2009-05-28 2012-10-04 Victoria Ballard Stem cell targeting
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
EP2475391B1 (en) 2009-09-09 2018-09-12 Centrose, LLC Extracellular targeted drug conjugates
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
US10817851B2 (en) 2009-12-23 2020-10-27 Aristocrat Technologies Australia Pty Limited System and method for cashless gaming
JP2013515776A (ja) 2009-12-29 2013-05-09 イェール ユニバ−シティ− 血管内皮増殖因子（ｖｅｇｆ）受容体のインヒビターおよびその使用方法
IN2012DN05017A (pt) 2010-01-14 2015-10-02 Univ Yale
WO2011119948A1 (en) * 2010-03-26 2011-09-29 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
DK2661447T3 (en) 2011-01-06 2015-11-02 Complix N V Alphabodies that specifically bind to cytokines or growth factors and / or cytokine or growth factor receptors
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
AR086044A1 (es) 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
DK2750713T3 (en) 2011-10-14 2015-12-21 Medimmune Ltd PYRROLOBENZODIAZEPINS AND CONJUGATES THEREOF
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
JP6307075B2 (ja) 2012-07-25 2018-04-18 セルデックス セラピューティクス，インコーポレーテッド 抗ｋｉｔ抗体及びその使用
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
WO2015112822A1 (en) 2014-01-24 2015-07-30 Kolltan Pharmaceuticals, Inc. Antibody-drug conjugates targeting kit receptor and uses thereof
WO2015179737A2 (en) 2014-05-23 2015-11-26 Kolltan Pharmaceuticals, Inc. Treatment of eosinophil or mast cell related disorders
HUE044040T2 (hu) 2014-08-06 2019-09-30 Pfizer Imidazopiridazin vegyületek
US11392902B2 (en) 2017-06-06 2022-07-19 United Parcel Service Of America, Inc. Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery

Also Published As

Publication number Publication date
CN110256559A (zh) 2019-09-20
MX360620B (es) 2018-11-09
ES2673847T3 (es) 2018-06-26
EP2877493A1 (en) 2015-06-03
NZ630363A (en) 2018-09-28
CN104812775A (zh) 2015-07-29
JP6307075B2 (ja) 2018-04-18
TW201408699A (zh) 2014-03-01
CA2880007A1 (en) 2014-01-30
JP2018138545A (ja) 2018-09-06
KR20150038278A (ko) 2015-04-08
MX2015000999A (es) 2015-11-13
TWI596113B (zh) 2017-08-21
US10781267B2 (en) 2020-09-22
NZ731881A (en) 2022-07-29
EP4063391A1 (en) 2022-09-28
US9605081B2 (en) 2017-03-28
BR112015001459A8 (pt) 2021-11-03
CN110256559B (zh) 2023-05-26
DK3381943T3 (da) 2022-05-16
US9334332B2 (en) 2016-05-10
DK2877493T3 (en) 2018-06-14
PH12015500113A1 (en) 2015-03-30
BR112015001459A2 (pt) 2017-07-04
WO2014018625A1 (en) 2014-01-30
AU2013295848B2 (en) 2018-05-24
ZA201500457B (en) 2021-07-28
JP2023062063A (ja) 2023-05-02
CA2880007C (en) 2021-12-28
US20170158778A1 (en) 2017-06-08
CN104812775B (zh) 2019-05-03
BR112015001459B1 (pt) 2023-02-14
JP6875302B2 (ja) 2021-05-19
IL236874A0 (en) 2015-03-31
US20190106510A1 (en) 2019-04-11
JP2021119779A (ja) 2021-08-19
EP3381943B1 (en) 2022-03-16
JP2015531752A (ja) 2015-11-05
US20220010027A1 (en) 2022-01-13
RU2681730C2 (ru) 2019-03-12
CN116574185A (zh) 2023-08-11
AU2013295848A1 (en) 2015-02-05
EP2877493B1 (en) 2018-03-21
US11891452B2 (en) 2024-02-06
SG11201500489YA (en) 2015-02-27
IL236874B (en) 2019-08-29
US20240150493A1 (en) 2024-05-09
US10184007B2 (en) 2019-01-22
US20140065168A1 (en) 2014-03-06
KR102268351B1 (ko) 2021-06-22
JP7230095B2 (ja) 2023-02-28
US20160311924A1 (en) 2016-10-27
RU2015106147A (ru) 2016-09-20
EP3381943A1 (en) 2018-10-03

Similar Documents

Publication Publication Date Title
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
HK1211038A1 (en) Anti-kit antibodies and uses thereof kit
HK1207092A1 (en) Anti-hla-b27 antibodies and uses thereof -hla-b27
IL238559A0 (en) Antibodies against ceacam5 and their use
HRP20190358T1 (hr) Antitijela protiv asic1 i njihova primjena
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
EP2668210A4 (en) ANTI-KIT ANTIBODIES AND ITS USES
GB201208372D0 (en) Antibodies and uses thereof